The DUO Trial: IPI-145 vs Ofatumumab in Relapsed or Refractory CLL or SLL

Julian Adams, PhD

Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale behind the DUO trial.

Clinical Pearls

Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale behind the DUO trial.

  • In this phase III trial, IPI-145 is being compared with ofatumumab in patients with relapsed or refractory CLL or SLL.
  • This trial is being conducted based on high nodal responses seen in a phase I trial.
  • IPI-145 has elicited responses in patients with the 17p deletion, a group that typically has a poor prognosis.